Cibus (CBUS) 10-Q 4 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 04, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Trading Symbol	CLXT
Entity Registrant Name	Calyxt, Inc.
Entity Central Index Key	0001705843
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		38,505,678
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38161
Entity Tax Identification Number	27-1967997
Entity Address, Address Line One	2800 Mount Ridge Road
Entity Address, City or Town	Roseville
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55113-1127
City Area Code	651
Local Phone Number	683-2807
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock (0.0001 par value)
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 13,922	$ 17,299
Short-term investments	0	11,698
Restricted cash	393	393
Accounts receivable	206	4,887
Inventory	1,674	1,383
Prepaid expenses and other current assets	1,057	3,930
Total current assets	17,252	39,590
Non-current restricted cash	598	597
Land, buildings, and equipment	21,476	22,860
Other non-current assets	195	280
Total assets	39,521	63,327
Current liabilities:
Accounts payable	1,037	929
Accrued expenses	1,139	2,891
Accrued compensation	2,284	1,950
Due to related parties	149	766
Current portion of financing lease obligations	387	364
Other current liabilities	147	45
Total current liabilities	5,143	6,945
Financing lease obligations	17,582	17,876
Long-term debt	0	1,518
Other non-current liabilities	971	113
Total liabilities	23,696	26,452
Stockholders’ equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized; 37,401,876 shares issued and 37,301,724 shares outstanding as of September 30, 2021, and 37,165,196 shares issued and 37,065,044 shares outstanding as of December 31, 2020	4	4
Additional paid-in capital	205,899	204,807
Common stock in treasury, at cost; 100,152 shares as of September 30, 2021, and December 31, 2020	(1,043)	(1,043)
Accumulated deficit	(189,035)	(166,893)
Total stockholders’ equity	15,825	36,875
Total liabilities and stockholders’ equity	$ 39,521	$ 63,327

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	37,401,876	37,165,196
Common stock, shares outstanding	37,301,724	37,065,044
Treasury stock, shares	100,152	100,152

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue	$ 7,762	$ 5,241	$ 24,044	$ 9,925
Cost of goods sold	8,281	7,060	26,553	16,265
Gross profit	(519)	(1,819)	(2,509)	(6,340)
Operating expenses:
Research and development	2,579	2,204	8,473	7,816
Selling, general, and administrative	3,859	4,523	11,595	15,988
Management fees	0	68	45	172
Restructuring costs	0	436	0	436
Total operating expenses	6,438	7,231	20,113	24,412
Loss from operations	(6,957)	(9,050)	(22,622)	(30,752)
Gain upon extinguishment of Payroll Protection Program Loan	0	0	1,528	0
Interest, net	(356)	(324)	(1,059)	(568)
Non-operating expenses	6	(102)	11	(121)
Loss before income taxes	(7,307)	(9,476)	(22,142)	(31,441)
Income taxes	0	0	0	0
Net loss	$ (7,307)	$ (9,476)	$ (22,142)	$ (31,441)
Basic and diluted net loss per share	$ (0.20)	$ (0.29)	$ (0.60)	$ (0.95)
Weighted average shares outstanding - basic and diluted	37,279,703	33,200,289	37,205,655	33,076,376
Anti-dilutive stock options, restricted stock units, and performance stock units	5,966,488	5,581,307	5,966,488	5,581,307

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares in Treasury [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Dec. 31, 2019	$ 62,508	$ 3	$ 185,588	$ (1,043)	$ (122,057)	$ 17
Beginning balance, shares at Dec. 31, 2019		32,951,329
Net loss	(31,441)				(31,441)
Stock-based compensation	3,638		3,638
Issuance of common stock	211		211
Issuance of common stock, shares		309,624
Shares withheld for net share settlement, shares		(17,792)
Other comprehensive income (loss)	(20)					(20)
Ending balance at Sep. 30, 2020	34,896	$ 3	189,437	(1,043)	(153,498)	(3)
Ending balance, shares at Sep. 30, 2020		33,243,161
Beginning balance at Jun. 30, 2020	43,553	$ 3	188,656	(1,043)	(144,022)	(41)
Beginning balance, shares at Jun. 30, 2020		33,040,520
Net loss	(9,476)				(9,476)
Stock-based compensation	570		570
Issuance of common stock	211		211
Issuance of common stock, shares		202,641
Other comprehensive income (loss)	38					38
Ending balance at Sep. 30, 2020	34,896	$ 3	189,437	(1,043)	(153,498)	$ (3)
Ending balance, shares at Sep. 30, 2020		33,243,161
Beginning balance at Dec. 31, 2020	36,875	$ 4	204,807	(1,043)	(166,893)
Beginning balance, shares at Dec. 31, 2020		37,065,044
Net loss	(22,142)				(22,142)
Stock-based compensation	865		865
Issuance of common stock	227		227
Issuance of common stock, shares		236,680
Ending balance at Sep. 30, 2021	15,825	$ 4	205,899	(1,043)	(189,035)
Ending balance, shares at Sep. 30, 2021		37,301,724
Beginning balance at Jun. 30, 2021	21,896	$ 4	204,663	(1,043)	(181,728)
Beginning balance, shares at Jun. 30, 2021		37,205,473
Net loss	(7,307)				(7,307)
Stock-based compensation	1,236		1,236
Issuance of common stock	0		0
Issuance of common stock, shares		96,251
Ending balance at Sep. 30, 2021	$ 15,825	$ 4	$ 205,899	$ (1,043)	$ (189,035)
Ending balance, shares at Sep. 30, 2021		37,301,724

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities
Net loss	$ (22,142)	$ (31,441)
Adjustments to reconcile net loss to net cash used by operating activities:
Gain upon extinguishment of Payroll Protection Program Loan	(1,528)	0
Depreciation and amortization	1,776	1,372
Stock-based compensation	865	3,638
Changes in operating assets and liabilities:
Accounts receivable	4,681	(1,310)
Due to/from related parties	(617)	(498)
Inventory	(291)	(3,359)
Prepaid expenses and other current assets	2,873	(707)
Accounts payable	108	86
Accrued expenses	(1,742)	1,717
Accrued compensation	334	(572)
Other	1,029	183
Net cash used by operating activities	(14,654)	(30,891)
Investing activities
Sales and (purchases) of short-term investments, net	11,698	(20,802)
Purchases of land, buildings, and equipment	(376)	(1,253)
Net cash provided (used) by investing activities	11,322	(22,055)
Financing activities
Proceeds from Payroll Protection Program loan	0	1,518
Repayments of financing lease obligations	(271)	(217)
Proceeds from the exercise of stock options	227	211
Net cash (used) provided by financing activities	(44)	1,512
Net decrease in cash, cash equivalents, and restricted cash	(3,376)	(51,434)
Cash, cash equivalents, and restricted cash - beginning of period	18,289	60,038
Cash, cash equivalents, and restricted cash – end of period	$ 14,913	$ 8,604

Basis of Presentation & Summary

Basis of Presentation & Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation & Summary of Significant Accounting Policies	1. BASIS OF PRESENTATION & SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The unaudited consolidated financial statements of Calyxt, Inc. (Calyxt or the Company) have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP or GAAP) for interim financial information and with the rules and regulations of the Securities and Exchange Commission (SEC) applicable to interim financial statements. In the Company's opinion, the accompanying consolidated financial statements reflect all adjustments necessary for a fair presentation of its statements of financial position, results of operations, and cash flows for the periods presented but they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. Except as otherwise disclosed herein, these adjustments consist of normal recurring items. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole or any other interim period. The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from these estimates. Certain prior year amounts have been reclassified to conform to the current year presentation. For further information, refer to the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 4, 2021. The accompanying Balance Sheet as of December 31, 2020, was derived from the audited consolidated financial statements. This Quarterly Report on Form 10-Q should be read in conjunction with the Company's consolidated financial statements and notes included in the Annual Report on Form 10-K for the year ended December 31, 2020. Risks and Uncertainties Calyxt is an early-stage company and has incurred net losses since its inception. As of September 30, 2021, the Company had an accumulated deficit of $ 189.0 million. The Company's net losses were $ 22.1 million for the nine months ended September 30, 2021, and the Company used $ 14.7 million of cash for operating activities for the nine months ended September 30, 2021. The Company's primary sources of liquidity are its cash and cash equivalents. As of September 30, 2021, the Company had $ 14.9 million of cash, cash equivalents, and restricted cash. The Company’s restricted cash is associated with its equipment financing leases and was $ 1.0 million as of September 30, 2021, with $ 0.4 million scheduled to be returned in December 2021. Current liabilities were $ 5.1 million as of September 30, 2021. On September 21, 2021, the Company entered into an Open Market Sale Agreement SM (the ATM Facility) with Jefferies LLC (Jefferies), acting as sole selling agent. Under the terms of the ATM Facility, the Company may, from time-to-time, issue common stock having an aggregate offering value of up to $ 50.0 million. At its discretion the Company determines the timing and number of shares to be issued under the ATM Facility. As of the date of this report, the Company has issued approximately 1.2 million shares of common stock under the ATM Facility for proceeds of $ 3.7 million net of commissions and payments for other share issuance costs. The Company’s current operating plans reflect a modest level of payments from customers from commercial activities in 2022, which when combined with planned spending and the current balance of cash and cash equivalents make it likely that it will require additional liquidity to continue operations under this business plan over the next 12 months. Absent payments from customers in excess of Calyxt’s operating plans or the ability to raise capital, the Company’s management believes it can implement various cost reduction and other cash-focused measures in order to manage liquidity for the next 12 months. The Company anticipates that it will continue to generate losses for the next several years before revenue is enough to support its operating capital requirements. Until the Company can generate substantial cash flow, it expects to finance a portion of future cash needs through cash on hand, commercialization activities, which may result in various types of revenue streams from (i) product sales from its proprietary BioFactory production system, and (ii) future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties; government or other third-party funding, public or private equity or debt financings, or the issuance of shares under the Company's ATM Facility. However, additional capital may not be available on reasonable terms, if at all. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms, it may have to significantly delay, scale back, or discontinue the development or commercialization of its activities. Failure to receive additional funding could cause the Company to cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, it could result in dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company's shares of common stock. Any of these events could significantly harm the Company's business, financial condition, and prospects. Net Loss Per Share Due to the Company's net loss position for the three and nine months ended September 30, 2021, and September 30, 2020 , all its outstanding stock options, restricted stock units, and performance stock units are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options and restricted stock units.

Financial Instruments Measured

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	9 Months Ended
	Sep. 30, 2021
Text Block [Abstract]
Financial Instruments Measured at Fair Value and Concentrations of Credit Risk	2. FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE AND CONCENTRATIONS OF CREDIT RISK Financial Instruments Measured at Fair Value and Financial Statement Presentation Financial instruments including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities have carrying values that approximate fair value. The Company measures short-term investments and commodity derivative contracts at fair value on a recurring basis. The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as of the measurement date as follows: Level 1: Fair values are based on unadjusted quoted prices in active trading markets for identical assets and liabilities. Level 2: Fair values are based on observable quoted prices other than those in Level 1, such as quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. Level 3: Fair values are based on at least one significant unobservable input for the asset or liability. Fair Value Measurements and Financial Statement Presentation As of September 30, 2021 , the Company had no financial instruments measured at fair value. The fair values of the Company's financial instruments measured at fair value and their respective levels in the fair value hierarchy as of December 31, 2020, were as follows: December 31, 2020 December 31, 2020 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 11,698 $ — $ — $ 11,698 $ — $ — $ — $ — Commodity derivative contracts 467 — — 467 — — — — Total $ 12,165 $ — $ — $ 12,165 $ — $ — $ — $ — The non-current portion of the Company's financing lease obligations are also considered a financial instrument, which it measures at fair value for disclosure purposes on a non-recurring basis. It is a Level 2 liability and had a fair value of $ 14.8 million as of September 30, 2021 , and a fair value of $ 15.2 million as of December 31, 2020. Commodity Price Risk Under the Company's former go-to-market strategy for its soybean product line, it entered into seed and grain production agreements with settlement values based on commodity futures market prices (Forward Purchase Contracts). These Forward Purchase Contracts allowed the counterparty to fix their sales prices at various times as defined in the contract. Upon delivery, the inventory was carried at historical cost but sold at prevailing market prices. As a result, the Company entered into hedging arrangements by selling futures contracts which converted its market exposure to these fixed prices to floating prices. The Company would maintain these hedging relationships until such grain inventory was sold to help stabilize margins. The Company did not account for these economic hedges as accounting hedges. The Company expected that any gains or losses from these hedging arrangements would be offset by gains or losses on the grain inventories when such grain inventories were sold. As a result of the continued wind-down of the soybean product line, the Company held no commodity derivative contracts as of September 30, 2021. Prior to August 1, 2020, the Company designated all of its commodity derivative contracts as cash flow hedges based on the nature of its business activities. As a result, all gains or losses associated with recording those commodity derivative contracts at fair value were recorded as a component of accumulated other comprehensive income (loss) (AOCI). The Company reclassified amounts from AOCI to cost of goods sold when the underlying products were sold to which those hedges related. For the three and nine months ended September 30, 2020, the Company reclassified a nominal amount from AOCI to cost of goods sold, and there were no such reclassifications in the same periods in 2021. Foreign Exchange Risk Foreign currency fluctuations affect the Company's foreign currency cash flows related primarily to payments to Cellectis. The Company's principal foreign currency exposure is to the euro. The Company does not hedge these exposures, and it does not believe that the current level of foreign currency risk is significant to its operations. Concentrations of Credit Risk The Company invests its cash, cash equivalents, and restricted cash in highly liquid securities and investment funds. It diversifies the risk posed by exceeding deposit insurance limits by allocating from time-to-time certain investments to a diverse portfolio of short-dated, high investment-grade securities, which the Company classifies as short-term investments that are recorded at fair value in its consolidated financial statements. The Company ensures the credit risk in this portfolio is in accordance with its internal policies and if necessary, makes changes to investments to ensure credit risk is minimized. The Company has not experienced any counterparty credit losses. As of September 30, 2021, the Company did not hold any short-term investments.

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related-Party Transactions	3. RELATED-PARTY TRANSACTIONS The Company is party to several agreements that govern its relationship with Cellectis, some of which require the Company to make payments to Cellectis. Pursuant to the Company's management services agreement with Cellectis, it incurred nominal management fee expenses for the three and nine months ended September 30, 2021, and 2020. Cellectis has also guaranteed the lease agreement for the Company's headquarters. Cellectis’ guarantee of the Company's obligations under the lease will terminate at the end of the second consecutive calendar year in which the Company's tangible net worth exceeds $ 300 million. TALEN ® is the Company's primary gene editing technology, and it is the foundation of its technology platform. TALEN ® technology was invented by researchers at the University of Minnesota and Iowa State University and exclusively licensed to Cellectis. The Company obtained an exclusive license for the TALEN ® technology for commercial use in plants from Cellectis. The Company also licenses other technology from Cellectis. Cellectis is entitled to royalties on any revenue the Company generates from sales of products less certain amounts as defined in the license agreement, royalties on certain cumulative revenue thresholds, and a percentage of any sublicense revenues. The Company has incurred nominal license and royalty fees for the three and nine months ended September 30, 2021, and 2020. The Company is also party to various agreements with the University of Minnesota, pursuant to which it has been granted both exclusive and non-exclusive license agreements that carry annual license fees, milestone payments, royalties, and associated legal fees. These agreements primarily relate to gene-editing tools, enabling technologies, and germplasm. The Company incurred nominal expenses pursuant to these agreements for the three and nine months ended September 30, 2021, and 2020.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders' Equity	4 . STOCKHOLDERS’ EQUITY ATM Facility On September 21, 2021, the Company entered into an ATM Facility with Jefferies, who is acting as sole selling agent for the ATM Facility. Under the terms of the ATM Facility, the Company may, from time-to-time, issue common stock having an aggregate offering value of up to $ 50.0 million. At its discretion the Company determines the timing and number of shares to be issued under the ATM Facility. As of September 30, 2021, the Company had not issued any shares of common stock under the ATM Facility. As of the date of this report, the Company has issued approximately 1.2 million shares of common stock under the ATM Facility for proceeds of $ 3.7 million net of commissions and payments for other share issuance costs.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	5. STOCK-BASED COMPENSATION The Company uses broad-based stock plans to attract and retain highly qualified officers and employees and to help ensure that management’s interests are aligned with those of its shareholders. The Company has also granted equity-based awards to directors, nonemployees, and certain employees of Cellectis. In December 2014, the Company adopted the Calyxt, Inc. Equity Incentive Plan (2014 Plan), which allowed for the grant of stock options, and in June 2017, it adopted the 2017 Omnibus Plan (2017 Plan), which allowed for the grant of stock options, restricted stock units, performance stock units, and other types of equity awards. On February 19, 2021, James Blome ceased serving as the Company's Chief Executive Officer. The Company recorded a benefit to earnings from a $ 2.5 million recapture of non-cash stock compensation expense from the forfeiture of Mr. Blome’s unvested stock options, restricted stock units, and performance stock units. On July 16, 2021, the Company filed a Registration Statement on Form S-8 with the SEC which registered an additional 4,299,904 shares of common stock that may be issued or delivered and sold pursuant to the 2017 Plan and 600,000 shares of common stock that may be issued or delivered and sold pursuant to the Calyxt, Inc. Employee Inducement Incentive Plan (the Inducement Plan). Shares of common stock are issuable under the Inducement Plan upon the settlement of performance stock units which were granted to Mr. Michael A. Carr in July 2021 as a material inducement to accept employment as the Company's President and Chief Executive Officer. As of September 30, 2021, 5,613,334 shares were registered and available for grant under effective registration statements, while 5,710,787 shares were available for grant in the form of stock options, restricted stock, restricted stock units, and performance stock units under the 2017 Plan. Stock-based awards currently outstanding also include awards granted under the 2014 Plan and the Inducement Plan. No further awards will be granted under either the 2014 Plan or the Inducement Plan. Stock Options The estimated fair values of stock options granted and the assumptions used for the Black-Scholes option pricing model were as follows: Nine Months Ended September 30, 2021 2020 Estimated fair values of stock options granted $ 3.93 $ 3.32 Assumptions: Risk-free interest rate 0.6 %- 1.1 % 0.3 %- 1.7 % Expected volatility 80.1 %- 82.0 % 77.4 %- 81.2 % Expected term (in years) 5.5 - 6.5 6.0 - 10.0 The Company estimates the fair value of each option on the grant date, or other measurement dates if applicable, using a Black-Scholes option-pricing model, which requires it to make predictive assumptions regarding employee exercise behavior, future stock price volatility, and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon yield curve at the date of grant for the expected term of the option. The Company estimates its future stock price volatility using the historical volatility of comparable public companies over the expected term of the option. The Company's expected term represents the period that options granted are expected to be outstanding determined using the simplified method. The Company does not, nor does it expect to, pay dividends. Option strike prices are set at 100 percent or more of the closing share price on the date of grant and generally vest over three to six years following the grant date. Options generally expire 10 years after the date of grant. Information on stock option activity is as follows: Options Weighted- Options Weighted- Balance as of December 31, 2020 2,347,663 $ 10.15 4,621,173 $ 10.30 Granted 656,959 5.70 Exercised ( 61,372 ) 3.70 Forfeited or expired ( 602,892 ) 10.84 Balance as of September 30, 2021 2,685,450 $ 10.18 4,613,868 $ 9.66 Stock-based compensation expense related to stock option awards is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 698 $ 187 $ 1,103 $ 2,439 As of September 30, 2021 , options outstanding and exercisable had no aggregate intrinsic value and the weighted average remaining contractual term was 5.8 years. Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Net cash proceeds $ — $ 211 $ 227 $ 211 Intrinsic value of options exercised $ — $ 179 $ 344 $ 179 As of September 30, 2021 , unrecognized compensation expense related to non-vested stock options was $ 5.9 million. This expense will be recognized over 26 months on average. Restricted Stock Units The Company grants restricted stock units which generally vest over three to five years after the date of grant. Information on restricted stock unit activity is as follows: Number of Weighted- Unvested balance at December 31, 2020 547,807 $ 9.49 Granted 346,981 4.99 Vested ( 165,137 ) 7.40 Forfeited ( 153,631 ) 11.85 Unvested balance at September 30, 2021 576,020 $ 6.75 The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Grant-date fair value $ 581 $ 1,079 $ 1,223 $ 2,270 Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 416 $ 269 $ ( 105 ) $ 865 As of September 30, 2021 , unrecognized compensation expense related to restricted stock units was $ 2.0 million. This expense will be recognized over 23 months on average. The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Deemed dividends from grants to Cellectis employees $ ( 84 ) $ 581 $ ( 55 ) $ 1,003 Performance Stock Units In June 2019, the Company granted 311,667 performance stock units under the 2017 Plan to three executive officers. The performance stock units will vest at 50 percent, 100 percent or 120 percent of the shares under the award at the end of a three-year performance period based upon increases in the value of the Company's common stock from the grant price of $ 12.48 . The performance stock units will be settled in restricted stock upon vesting, with restrictions on transfer lapsing on the second anniversary of the restricted stock issuance date. During the nine months ended September 30, 2021 , the Company recognized a benefit from the forfeiture of 166,667 performance stock units held by Mr. Blome, its former chief executive officer. In July 2021, the Company granted 600,000 performance stock units under the Inducement Plan to Mr. Carr, its President and Chief Executive Officer. The performance stock units will vest if the Company’s stock remains above three specified price levels for 30 calendar days over the three-year performance period. The performance stock units will be settled in unrestricted shares of the Company's common stock on the vesting date. The estimated fair values of performance stock units granted in 2021, and the assumptions used for the Monte Carlo simulation pricing model were as follows: Three Months Ended September 30, 2021 Estimated fair values of performance stock units granted: At least $12 per share $ 2.16 At least $15 per share $ 1.89 At least $20 per share $ 1.55 Assumptions: Risk-free interest rate 0.4 % Expected volatility 90.0 % Expected term (in years) 3.0 The Company estimated the fair value of each tranche of the performance stock units on the grant date using the Monte Carlo simulation pricing model, which required it to make predictive assumptions as to the expected term of the grant, future stock price volatility, and dividend yield. The Company estimates the risk-free interest rate based on the United States Treasury zero-coupon yield curve at the date of grant for the expected term of the option. Expected volatility was based on the historical volatility of the Company’s common stock over the expected term. The expected term represents the expected service period of the performance stock units granted. Stock-based compensation expense related to performance stock units is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 122 $ 114 $ ( 133 ) $ 334 As of September 30, 2021 , unrecognized compensation expense related to performance stock units was $ 1.7 million. This expense will be recognized over 34 months on average

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	6. INCOME TAXES The Company provides for a valuation allowance when it is more likely than not that it will not realize a portion of the deferred tax assets. The Company has established a full valuation allowance for deferred tax assets due to the uncertainty that enough taxable income will be generated in the taxing jurisdiction to utilize the assets. Therefore, the Company has not reflected any benefit of such deferred tax assets in the accompanying consolidated financial statements. As of September 30, 2021, there were no material changes to what the Company disclosed regarding tax uncertainties or penalties as of December 31, 2020 .

Leases, Other Commitments, and

Leases, Other Commitments, and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Leases, Other Commitments, and Contingencies	7. LEASES, OTHER COMMITMENTS, AND CONTINGENCIES Litigation and Claims The Company is not currently a party to any material pending legal proceeding. Leases The Company leases its headquarters facility, office equipment, and other items. The Company's headquarters lease involved the sale of land and improvements to a third-party who then constructed the facility. This lease is considered a financing lease. The Company also has an equipment financing arrangement that is considered a financing lease. This arrangement has a term of four years for each draw. The Company is required to deposit cash into a restricted account in an amount equal to the future rent payments required by the lease. As of September 30, 2021 , restricted cash totaled $ 1.0 million. The Company has the option to request the return of excess collateral annually in December, and the amount it expects to receive in December 2021 is reflected as a current asset. Rent expense from operating leases was as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Rent expense from operating leases $ 10 $ 24 $ 34 $ 71 Other Commitments As of September 30, 2021 , the Company had noncancelable commitments to purchase grain from growers at dates throughout 2021 aggregating approximately $ 0.1 million based on current commodity futures market prices, other payments to growers, and estimated yields per acre. This commitment is not recorded in the consolidated financial statements because the Company has not taken delivery of the grain as of September 30, 2021 .

Supplemental Information

Supplemental Information	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Information	8. SUPPLEMENTAL INFORMATION Certain balance sheet amounts are as follows: As of September 30, As of December 31, In Thousands 2021 2020 Accounts Receivable: Accounts receivable $ 199 $ 4,317 Receivables from growers 7 570 Allowance for doubtful accounts — — Total $ 206 $ 4,887 Certain statements of operations amounts are as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Stock compensation expense: Research and development $ 252 $ ( 84 ) $ 1,061 $ 723 Selling, general, and administrative 984 654 ( 196 ) 2,915 Total $ 1,236 $ 570 $ 865 $ 3,638 Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Interest, net: Interest expense $ ( 356 ) $ ( 369 ) $ ( 1,075 ) $ ( 1,112 ) Interest income — 45 16 544 Total $ ( 356 ) $ ( 324 ) $ ( 1,059 ) $ ( 568 ) Certain balance sheet and statements of cash flows amounts are as follows: As of September 30, As of December 31, As of September 30, In Thousands 2021 2020 2020 Cash, cash equivalents, restricted cash, and short-term investments: Cash and cash equivalents $ 13,922 $ 17,299 $ 7,170 Restricted cash 393 393 393 Non-current restricted cash 598 597 1,041 Total cash, cash equivalents, and restricted cash 14,913 18,289 8,604 Short-term investments — 11,698 20,802 Total $ 14,913 $ 29,987 $ 29,406

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	9. SEGMENT INFORMATION The Company operates in a single reportable segment, the development and commercialization of products derived from plant cells. Products commercialized to date have included a soybean and its derivative products, including oil and meal. The Company's current commercial focus is North America.

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Long-Term Debt	10. LONG-TERM DEBT The Company's long-term debt was comprised of a $ 1.5 million promissory note pursuant to the Paycheck Protection Program (the PPP loan) established by the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) implemented by the U.S. Small Business Administration (SBA). The Company received the funds under the PPP loan on April 19, 2020. Subject to certain conditions, the PPP loan and accrued interest were eligible to be forgiven in whole or in part by applying for forgiveness pursuant to the CARES Act and the Paycheck Protection Program. In order to be eligible for forgiveness, the proceeds of the PPP loan were required to be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40 percent of the amount applied to non-payroll costs. The Company applied the proceeds from the PPP loan toward qualifying expenses. On October 21, 2020, as modified December 29, 2020, the Company applied for forgiveness of the full principal amount and all accrued interest. O n April 8, 2021, the Company was notified by the SBA that the full principal amount and all accrued interest of the PPP loan had been forgiven. Accordingly, the Company recognized a gain upon the extinguishment of the PPP loan for $ 1.5 million during the second quarter of 2021.

Restructuring Costs

Restructuring Costs	9 Months Ended
	Sep. 30, 2021
Restructuring Costs [Abstract]
Restructuring costs	11. RESTRUCTURING COSTS On August 4, 2020, the Company approved a move to a streamlined go-to-market strategy for its soybean product line. The impact of the action included staffing adjustments related to soybean processing and product sales, as well as the gradual exit of all supply chain contractual commitments that were not associated with the ongoing soybean seed go-to-market strategy. In the three months ended September 30, 2020, the Company recorded $ 0.4 million of cash charges for severance and other related payments and also recorded a $ 0.9 million recapture benefit of non-cash stock compensation expense from the forfeiture or modification of unvested stock awards. The Company did not incur any other material costs from the disposal of any assets or contractual terminations in the three and nine months ended September 30, 2021, and 2020. As of December 31, 2020, all severance and transitional expenses were recorded, with $ 0.4 million to be paid during 2021. As of September 30, 2021, all amounts related to the restructuring had been paid.

Basis of Presentation & Summa_2

Basis of Presentation & Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Risks and Uncertainties	Risks and Uncertainties Calyxt is an early-stage company and has incurred net losses since its inception. As of September 30, 2021, the Company had an accumulated deficit of $ 189.0 million. The Company's net losses were $ 22.1 million for the nine months ended September 30, 2021, and the Company used $ 14.7 million of cash for operating activities for the nine months ended September 30, 2021. The Company's primary sources of liquidity are its cash and cash equivalents. As of September 30, 2021, the Company had $ 14.9 million of cash, cash equivalents, and restricted cash. The Company’s restricted cash is associated with its equipment financing leases and was $ 1.0 million as of September 30, 2021, with $ 0.4 million scheduled to be returned in December 2021. Current liabilities were $ 5.1 million as of September 30, 2021. On September 21, 2021, the Company entered into an Open Market Sale Agreement SM (the ATM Facility) with Jefferies LLC (Jefferies), acting as sole selling agent. Under the terms of the ATM Facility, the Company may, from time-to-time, issue common stock having an aggregate offering value of up to $ 50.0 million. At its discretion the Company determines the timing and number of shares to be issued under the ATM Facility. As of the date of this report, the Company has issued approximately 1.2 million shares of common stock under the ATM Facility for proceeds of $ 3.7 million net of commissions and payments for other share issuance costs. The Company’s current operating plans reflect a modest level of payments from customers from commercial activities in 2022, which when combined with planned spending and the current balance of cash and cash equivalents make it likely that it will require additional liquidity to continue operations under this business plan over the next 12 months. Absent payments from customers in excess of Calyxt’s operating plans or the ability to raise capital, the Company’s management believes it can implement various cost reduction and other cash-focused measures in order to manage liquidity for the next 12 months. The Company anticipates that it will continue to generate losses for the next several years before revenue is enough to support its operating capital requirements. Until the Company can generate substantial cash flow, it expects to finance a portion of future cash needs through cash on hand, commercialization activities, which may result in various types of revenue streams from (i) product sales from its proprietary BioFactory production system, and (ii) future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties; government or other third-party funding, public or private equity or debt financings, or the issuance of shares under the Company's ATM Facility. However, additional capital may not be available on reasonable terms, if at all. If the Company is unable to raise additional capital in a sufficient amount or on acceptable terms, it may have to significantly delay, scale back, or discontinue the development or commercialization of its activities. Failure to receive additional funding could cause the Company to cease operations, in part or in full. If the Company raises additional funds through the issuance of additional debt or equity securities, it could result in dilution to its existing stockholders and increased fixed payment obligations, and these securities may have rights senior to those of the Company's shares of common stock. Any of these events could significantly harm the Company's business, financial condition, and prospects.
Net Loss Per Share	Net Loss Per Share Due to the Company's net loss position for the three and nine months ended September 30, 2021, and September 30, 2020 , all its outstanding stock options, restricted stock units, and performance stock units are considered anti-dilutive and excluded from the calculation of net loss per share. Accordingly, the treasury method was not used in determining the number of anti-dilutive stock options and restricted stock units.

Financial Instruments Measure_2

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk (Tables)	9 Months Ended
	Sep. 30, 2021
Text Block [Abstract]
Summary of Fair Value Measurements and Financial Statement Presentation	The fair values of the Company's financial instruments measured at fair value and their respective levels in the fair value hierarchy as of December 31, 2020, were as follows: December 31, 2020 December 31, 2020 Fair Values of Assets Fair Values of Liabilities In Thousands Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Other items reported at fair value: Short-term investments $ 11,698 $ — $ — $ 11,698 $ — $ — $ — $ — Commodity derivative contracts 467 — — 467 — — — — Total $ 12,165 $ — $ — $ 12,165 $ — $ — $ — $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model	The estimated fair values of stock options granted and the assumptions used for the Black-Scholes option pricing model were as follows: Nine Months Ended September 30, 2021 2020 Estimated fair values of stock options granted $ 3.93 $ 3.32 Assumptions: Risk-free interest rate 0.6 %- 1.1 % 0.3 %- 1.7 % Expected volatility 80.1 %- 82.0 % 77.4 %- 81.2 % Expected term (in years) 5.5 - 6.5 6.0 - 10.0 The Company
Summary of Stock Option Activity	Information on stock option activity is as follows: Options Weighted- Options Weighted- Balance as of December 31, 2020 2,347,663 $ 10.15 4,621,173 $ 10.30 Granted 656,959 5.70 Exercised ( 61,372 ) 3.70 Forfeited or expired ( 602,892 ) 10.84 Balance as of September 30, 2021 2,685,450 $ 10.18 4,613,868 $ 9.66
Schedule of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised	Net cash proceeds from the exercise of stock options less shares used for minimum withholding taxes and the intrinsic value of options exercised were as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Net cash proceeds $ — $ 211 $ 227 $ 211 Intrinsic value of options exercised $ — $ 179 $ 344 $ 179
Summary of Activity of Restricted Stock Units	Information on restricted stock unit activity is as follows: Number of Weighted- Unvested balance at December 31, 2020 547,807 $ 9.49 Granted 346,981 4.99 Vested ( 165,137 ) 7.40 Forfeited ( 153,631 ) 11.85 Unvested balance at September 30, 2021 576,020 $ 6.75
Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested	The total grant-date fair value of restricted stock unit awards that vested is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Grant-date fair value $ 581 $ 1,079 $ 1,223 $ 2,270
Summary of Stock-Based Compensation Granted As Deemed Dividends	The Company accounts for stock-based compensation awards granted to employees of Cellectis as deemed dividends. The Company recorded deemed dividends as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Deemed dividends from grants to Cellectis employees $ ( 84 ) $ 581 $ ( 55 ) $ 1,003
Summary of Fair Values of Performance Stock Units Granted and Assumptions used in Monte Carlo Simulation Pricing Model	The estimated fair values of performance stock units granted in 2021, and the assumptions used for the Monte Carlo simulation pricing model were as follows: Three Months Ended September 30, 2021 Estimated fair values of performance stock units granted: At least $12 per share $ 2.16 At least $15 per share $ 1.89 At least $20 per share $ 1.55 Assumptions: Risk-free interest rate 0.4 % Expected volatility 90.0 % Expected term (in years) 3.0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to stock option awards is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 698 $ 187 $ 1,103 $ 2,439
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to restricted stock units is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 416 $ 269 $ ( 105 ) $ 865
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based Compensation Expense	Stock-based compensation expense related to performance stock units is as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Stock-based compensation expense $ 122 $ 114 $ ( 133 ) $ 334

Leases, Other Commitments, an_2

Leases, Other Commitments, and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Lease Cost [Abstract]
Summary of Rent Expense from Operating Leases	Rent expense from operating leases was as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Rent expense from operating leases $ 10 $ 24 $ 34 $ 71

Supplemental Information (Table

Supplemental Information (Tables)	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Certain Balance Sheet Amounts	Certain balance sheet amounts are as follows: As of September 30, As of December 31, In Thousands 2021 2020 Accounts Receivable: Accounts receivable $ 199 $ 4,317 Receivables from growers 7 570 Allowance for doubtful accounts — — Total $ 206 $ 4,887
Schedule of Certain Statements of Operations Amounts	Certain statements of operations amounts are as follows: Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Stock compensation expense: Research and development $ 252 $ ( 84 ) $ 1,061 $ 723 Selling, general, and administrative 984 654 ( 196 ) 2,915 Total $ 1,236 $ 570 $ 865 $ 3,638 Three Months Ended September 30, Nine Months Ended September 30, In Thousands 2021 2020 2021 2020 Interest, net: Interest expense $ ( 356 ) $ ( 369 ) $ ( 1,075 ) $ ( 1,112 ) Interest income — 45 16 544 Total $ ( 356 ) $ ( 324 ) $ ( 1,059 ) $ ( 568 )
Schedule of Certain Statements of Balance sheet and cash flows amounts	Certain balance sheet and statements of cash flows amounts are as follows: As of September 30, As of December 31, As of September 30, In Thousands 2021 2020 2020 Cash, cash equivalents, restricted cash, and short-term investments: Cash and cash equivalents $ 13,922 $ 17,299 $ 7,170 Restricted cash 393 393 393 Non-current restricted cash 598 597 1,041 Total cash, cash equivalents, and restricted cash 14,913 18,289 8,604 Short-term investments — 11,698 20,802 Total $ 14,913 $ 29,987 $ 29,406

Basis of Presentation & Summa_3

Basis of Presentation & Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accumulated deficit	$ (189,035)		$ (189,035)		$ (166,893)
Net loss	(7,307)	$ (9,476)	(22,142)	$ (31,441)
Net cash used by operating activities			14,654	30,891
Restricted cash	393	393	393	393	393
Cash expense for separation-related payments	400		400
Current liabilities	5,143		5,143		6,945
Total cash, cash equivalents, and restricted cash	$ 14,913	$ 8,604	$ 14,913	$ 8,604	$ 18,289	$ 60,038
Common stock, shares issued	37,401,876		37,401,876		37,165,196
Equipment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Restricted cash	$ 1,000		$ 1,000
ATM Facility [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares issued	1,200,000		1,200,000
Proceeds from common stock issuance			$ 3,700
ATM Facility [Member] | Jefferies LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate common stock offering value			$ 50,000

Financial Instruments Measure_3

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Summary of Fair Value Measurements and Financial Statement Presentation (Detail) $ in Thousands	Dec. 31, 2020USD ($)
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	$ 12,165
Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	11,698
Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	467
Level 1 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	12,165
Level 1 [Member] | Short Term Investments [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	11,698
Level 1 [Member] | Commodity Derivative Contracts [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair Values of Assets	$ 467

Financial Instruments Measure_4

Financial Instruments Measured at Fair Value and Concentrations of Credit Risk - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Fair Value Non-recurring [Member] | Level 2 [Member]
Fair Value Concentration Of Risk Financial Statement Captions [Line Items]
Fair value of financing leases	$ 14.8	$ 15.2

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail)	Sep. 30, 2021USD ($)
Cellectis [Member]
Related Party Transaction [Line Items]
Minimum net worth required	$ 300,000,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common stock, shares issued	37,401,876	37,165,196
ATM Facility [Member]
Class of Stock [Line Items]
Proceeds from common stock issuance	$ 3.7
Common stock, shares issued	1,200,000
ATM Facility [Member] | Jefferies LLC [Member]
Class of Stock [Line Items]
Aggregate common stock offering value	$ 50

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Jul. 16, 2021	Feb. 19, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	5,613,334
Common Stock Shares Issued	37,401,876			37,165,196
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant	5,710,787
Number of common shares available for issue		4,299,904
Calyxt, Inc. Equity Employee Inducement Incentive Plan [Member] | PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares registered and available for grant		600,000
Mr. Blome [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected benefit to earnings from recapture of non-cash stock compensation expense			$ (2.5)

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Fair Values of Stock Options Granted and Assumptions used in Black-Scholes Model (Detail) - Stock Options [Member] - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair values of stock options granted	$ 3.93	$ 3.32
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.60%	0.30%
Expected volatility	80.10%	77.40%
Expected term (in years)	5 years 6 months	6 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.10%	1.70%
Expected volatility	82.00%	81.20%
Expected term (in years)	6 years 6 months	10 years

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options priced at fair market value, percent	100.00%
Stock option expiration period	10 years
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option, vesting period	6 years
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value outstanding	$ 0
Aggregate intrinsic value exercisable	$ 0
Weighted average remaining contractual term	5 years 9 months 18 days
Unrecognized stock-based compensation expense related to non-vested stock options	$ 5,900
Unrecognized stock-based compensation expense, expected recognition weighted-average period	26 months

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Exercisable, Beginning Balance | shares	2,347,663
Options Exercisable, Ending Balance | shares	2,685,450
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 10.15
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 10.18
Options Outstanding, Beginning Balance | shares	4,621,173
Options Outstanding, Granted | shares	656,959
Options Outstanding, Exercised | shares	(61,372)
Options Outstanding, Forfeited or expired | shares	(602,892)
Options Outstanding, Ending Balance | shares	4,613,868
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 10.30
Weighted-Average Exercise Price Per Share, Granted | $ / shares	5.70
Weighted-Average Exercise Price Per Share, Exercised | $ / shares	3.70
Weighted-Average Exercise Price Per Share, Forfeited or expired | $ / shares	10.84
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	$ 9.66

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Related to Stock Option Awards (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,236	$ 570	$ 865	$ 3,638
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 698	$ 187	$ 1,103	$ 2,439

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Net Cash Proceeds from Exercise of Stock Options Less Shares Used for Minimum Withholding Taxes and Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Net cash proceeds	$ 0	$ 211	$ 227	$ 211
Intrinsic value of options exercised	$ 0	$ 179	$ 344	$ 179

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	6 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to restricted stock units	$ 2
Unrecognized stock-based compensation expense, expected recognition weighted-average period	23 months
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted Stock Units [Member] | 2017 Omnibus Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Activity of Restricted Stock Units (Detail) - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units outstanding, Unvested beginning balance | shares	547,807
Number of restricted stock units outstanding, Granted | shares	346,981
Number of restricted stock units outstanding, Vested | shares	(165,137)
Number of restricted stock units outstanding, Forfeited | shares	(153,631)
Number of restricted stock units outstanding, Unvested ending balance | shares	576,020
Weighted-average grant date fair value, Unvested beginning balance | $ / shares	$ 9.49
Weighted-average grant date fair value, Granted | $ / shares	4.99
Weighted-average grant date fair value, Vested | $ / shares	7.40
Weighted-average grant date fair value, Forfeited | $ / shares	11.85
Weighted-average grant date fair value, Unvested ending balance | $ / shares	$ 6.75

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Grant Date Fair Value of Restricted Stock Unit Awards Vested (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant-date fair value	$ 581	$ 1,079	$ 1,223	$ 2,270

Stock-Based Compensation - Su_7

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Restricted Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,236	$ 570	$ 865	$ 3,638
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 416	$ 269	$ (105)	$ 865

Stock-Based Compensation - Su_8

Stock-Based Compensation - Summary of Stock-Based Compensation Granted as Deemed Dividends (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Nonemployee Restricted Stock Units [Member] | Cellectis [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deemed dividends from grants to Cellectis employees	$ (84)	$ 581	$ (55)	$ 1,003

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Stock Units - Additional Information (Detail) $ / shares in Units, $ in Millions	1 Months Ended		9 Months Ended
	Jul. 31, 2021dshares	Jun. 30, 2019$ / sharesshares	Sep. 30, 2021USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted			5,613,334
2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted			5,710,787
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to performance stock units | $			$ 1.7
Unrecognized stock-based compensation expense, expected recognition weighted-average period			34 months
Performance Stock Units [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Increase in common stock starting price | $ / shares		$ 12.48
Performance Stock Units [Member] | Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Consecutive trading day | d	30
Performance Stock Units [Member] | Tranche One [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		50.00%
Performance Stock Units [Member] | Tranche Two [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		100.00%
Performance Stock Units [Member] | Tranche Three [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		120.00%
Performance Stock Units [Member] | Mr Carr [Member] | Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted	600,000
Performance Stock Units [Member] | Mr. Blome [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Benefit from forfeiture of stock			166,667
Performance Stock Units [Member] | Three Executive Officers [Member] | 2017 Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance stock, shares granted		311,667

Stock-Based Compensation - Su_9

Stock-Based Compensation - Summary of Fair Values of Performance Stock Units Granted and Assumptions used in Monte Carlo Simulation Pricing Model (Detail) - Performance Shares [Member]	3 Months Ended
	Sep. 30, 2021$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate	0.40%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate	90.00%
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1	3 years
At Least Twelve Per Share [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Estimated Fair Values Of Performance Stock Units Granted	$ 2.16
At Least Fifteen Per Share [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Estimated Fair Values Of Performance Stock Units Granted	1.89
At Least Twenty Per Share [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Estimated Fair Values Of Performance Stock Units Granted	$ 1.55

Stock-Based Compensation - S_10

Stock-Based Compensation - Summary of Stock-Based Compensation Expenses Related to Performance Stock Units (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,236	$ 570	$ 865	$ 3,638
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 122	$ 114	$ (133)	$ 334

Leases, Other Commitments, an_3

Leases, Other Commitments, and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Other Commitments [Line Items]
Restricted cash	$ 393	$ 393	$ 393
Forward purchase noncancelable commitments amount	$ 100
Equipment [Member]
Other Commitments [Line Items]
Lease term	4 years
Restricted cash	$ 1,000

Leases, Other Commitments, an_4

Leases, Other Commitments, and Contingencies - Summary of Rent Expense from Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating Leases Rent Expense [Abstract]
Rent expense from operating leases	$ 10	$ 24	$ 34	$ 71

Supplemental Information - Summ

Supplemental Information - Summary of Certain Balance Sheet Amounts (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accounts Receivable:
Accounts receivable	$ 199	$ 4,317
Allowance for doubtful accounts	0	0
Total	206	4,887
Growers [Member]
Accounts Receivable:
Accounts receivable	$ 7	$ 570

Supplemental Information - Su_2

Supplemental Information - Summary of Certain Statements of Operations Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 1,236	$ 570	$ 865	$ 3,638
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	252	(84)	1,061	723
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock compensation expense	$ 984	$ 654	$ (196)	$ 2,915

Supplemental Information - Su_3

Supplemental Information - Summary of Components of Interest, Net (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Interest expense	$ (356)	$ (369)	$ (1,075)	$ (1,112)
Interest income	0	45	16	544
Total	$ (356)	$ (324)	$ (1,059)	$ (568)

Supplemental Information - Su_4

Supplemental Information - Summary of Certain Statements of Balance Sheet and Cash Flows Amounts (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Cash and cash equivalents	$ 13,922	$ 17,299	$ 7,170
Restricted cash	393	393	393
Non-current restricted cash	598	597	1,041
Total cash, cash equivalents, and restricted cash	14,913	18,289	8,604	$ 60,038
Short-term investments	0	11,698	20,802
Total	$ 14,913	$ 29,987	$ 29,406

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 08, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Apr. 19, 2020
Debt Instrument [Line Items]
Gain on extinguishment of Payroll Protection Program Loan		$ 0	$ 0		$ 1,528	$ 0
PPP loan
Debt Instrument [Line Items]
Loan, face amount							$ 1,500
Forgiveness eligibility description					In order to be eligible for forgiveness, the proceeds of the PPP loan were required to be applied to certain eligible expenses, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, with not more than 40 percent of the amount applied to non-payroll costs.
Description of loan forgiveness status	applied the proceeds from the PPP loan toward qualifying expenses. On October 21, 2020, as modified December 29, 2020, the Company applied for forgiveness of the full principal amount and all accrued interest. On April 8, 2021, the Company was notified by the SBA that the full principal amount and all accrued interest of the PPP loan had been forgiven. Accordingly, the Company recognized a gain upon the extinguishment of the PPP loan for $1.5 million during the second quarter of 2021.
Gain on extinguishment of Payroll Protection Program Loan				$ 1,500

Restructuring Costs (Additional

Restructuring Costs (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Severance cost		$ 400
Severance and transitional expenses to be paid					$ 400
Non cash stock-based compensation expense	$ (1,236)	(570)	$ (865)	$ (3,638)
Unvested Stock Awards [Member]
Restructuring Cost and Reserve [Line Items]
Non cash stock-based compensation expense		$ (900)